Zelira Therapeutics (ASX:ZLD) secures $33m to advance HOPE 1 autism therapy through U.S. FDA trials

Zelira Therapeutics Limited has closed a transformative US$32.98 million investment into its HOPE 1 Special Purpose Vehicle, with New York-based TGC Biotechnology Fund, P.S. (ThirdGate Capital) acquiring a 50 percent fully diluted stake. The capital raise values the HOPE 1 SPV at US$65.96 million and Zelira’s retained interest at approximately US$26.18 million. The proceeds will fund Phase 1 through Phase 3 clinical trials of HOPE 1 under the United States Food and Drug Administration’s 505(b)(2) regulatory pathway. The investment positions HOPE 1 to potentially secure Orphan Drug Designation for treating Phelan-McDermid Syndrome comorbid with autism, which would unlock market exclusivity and accelerated development incentives. The move sent Zelira Therapeutics Limited’s share price surging by over 129 percent in a single session on the Australian Securities Exchange.

Why is the HOPE 1 SPV structure pivotal for Zelira’s U.S. clinical ambitions in autism therapeutics?

The creation and funding of Zelira-Hope-1, LLC as a standalone SPV reflect a deliberate capital allocation and risk containment strategy for Zelira Therapeutics Limited. By contributing proprietary intellectual property and real-world data in exchange for equity, the company has managed to externalize clinical development risk while preserving economic upside. This approach effectively shields Zelira’s broader balance sheet from dilution and execution volatility, offering a scalable template for advancing other cannabinoid assets through the U.S. Food and Drug Administration process.

The US$33 million infusion will directly fund formal Investigational New Drug submissions, human dosing, and eventual pivotal trials. ThirdGate Capital will hold 6.6 million Series A Preferred Units, accounting for half of the SPV’s capital structure on a fully diluted basis. Zelira Therapeutics Limited will retain 5.2 million units, or 39.7 percent, with the remainder allocated to early institutional investors and a management incentive pool. No spin-out or public listing of the SPV is currently planned, suggesting long-term strategic alignment between the parent and the project vehicle.

The structure allows Zelira to benefit from milestone achievements without committing further balance sheet resources. According to Zelira’s Chairman Osagie Imasogie, who will also serve as Executive Chairman of the SPV, the funding represents a crucial pivot from foundational investment to regulatory execution. The inclusion of previous backers, such as The 2011 Forman Investment Trust and Mr. Malik Majeed, underscores continuity and board-level cohesion across phases.

How does this position HOPE 1 to capture regulatory and commercial tailwinds in rare disease markets?

Zelira Therapeutics Limited has pursued a focused path to secure regulatory endorsement for HOPE 1 by targeting Phelan-McDermid Syndrome with comorbid autism as its first indication. This genetically defined and clinically rare subset of the autism spectrum qualifies under the U.S. Food and Drug Administration’s criteria for Orphan Drug Designation. If granted, Zelira could receive seven years of market exclusivity post-approval, tax credits for clinical development, and potential fast-track status.

In its Pre-IND meeting with the U.S. Food and Drug Administration, completed in the second quarter of 2024, Zelira received agency alignment on the clinical plan, the rare disease qualification of PMS, and the rationale for its proposed 505(b)(2) route. This pathway allows developers to rely on existing safety data from prior drug approvals while supplementing with new efficacy and formulation studies. It is particularly well suited for drug repurposing and cannabinoid-based therapies, where real-world data can be leveraged to expedite early stages of regulatory review.

The SPV has appointed iNGENū CRO Pty Ltd as its Contract Research Organisation for the entire clinical development lifecycle. The Phase 1 and 2 programs have a combined budget of US$17.69 million, with Phase 3 expected to cost US$14.06 million. The trial will be the first formal dosing of HOPE 1 in a U.S. FDA-compliant setting, marking a major milestone for Zelira’s transition from revenue-generating cannabinoid formulations to investigational drug sponsors.

What does the board structure and governance reveal about execution discipline and investor oversight?

The board of the SPV has been constituted to reflect the governance rights of both capital and intellectual property contributors. ThirdGate Capital has designated three out of five directors, including Marlon Thomas and Cynthia Parrish, with one seat pending appointment. Zelira Therapeutics Limited has designated two seats, occupied by Osagie Imasogie and Dr. Donna Gentile O’Donnell. This arrangement gives ThirdGate operating control but maintains substantive Zelira oversight, ensuring alignment on both scientific and commercial milestones.

Management participation has also been tightly structured. The SPV has carved out a 4.88 percent fully diluted equity incentive pool, subject to standard vesting terms. Half of these units will vest upon U.S. Food and Drug Administration approval of HOPE 1, while the remaining half will vest over a three-year period. All allocations must be approved by ThirdGate Capital, reinforcing a performance-driven and capital-protected framework.

This dual-vesting mechanism not only ties rewards to regulatory outcomes but ensures continuity across the multi-phase trial timeline. It also reflects ThirdGate’s standard private equity playbook, which privileges board control, structured dilution, and milestone-based capital unlocking. For a sub–$10 million market capitalization firm like Zelira Therapeutics Limited, this disciplined structuring sends a strong signal to institutional capital markets.

How does HOPE 1 connect to Zelira’s broader pipeline and commercialization outlook?

The HOPE brand is already generating revenue in Australia and selected U.S. markets including Pennsylvania, Louisiana, and Washington, D.C. The two currently commercialized formulations, while not U.S. Food and Drug Administration approved, provide a clinical and anecdotal data lake that supports the 505(b)(2) narrative. With HOPE 1’s transition into the formal regulatory pathway, Zelira is leveraging both pre-commercial validation and regulatory arbitrage to scale impact without overextending its capital base.

Zelira is also preparing to commercialize ZENIVOL in Germany through a local partnership with Adjupharm GmbH, having received recent approval from German regulators. The company’s broader prescription portfolio includes cannabinoid-based candidates for insomnia and chronic pain. Its over-the-counter verticals have produced revenue via oral care products with SprinJeneCBD and the acne-focused RAF FIVE™ brand.

Zelira’s proprietary technology platform includes Enhanced Distillate Capture and Dissolution Matrix (EDCDM), marketed as Zyraydi™, which enables pharmaceutical-grade oral cannabinoid dosage forms. This positions the company to eventually manufacture capsules and tablets that conform to drug monograph and uniformity standards, solving a key limitation in the cannabis drug formulation space.

Although the HOPE 1 SPV is not being spun out at this time, the success of the vehicle could unlock future opportunities to ring-fence other pipeline candidates using a similar capital-light, IP-heavy structure. Zelira’s leadership has previously signaled interest in building a diversified cannabinoid asset platform with optionality around exit or licensing events.

How are public markets interpreting this move, and what does it imply about sentiment?

On January 16, 2026, shares of Zelira Therapeutics Limited soared by 129 percent to AUD 0.825 on the Australian Securities Exchange, supported by a trading volume of over 710,000 shares. This represents a 30.95 percent one-year return and catapults the company back into retail investor attention after a long period of subdued performance. Zelira’s market capitalization now sits at approximately AUD 9.82 million, based on 11.9 million outstanding ordinary shares.

Despite the surge, Zelira remains ranked 2,000 out of 2,315 companies on the ASX, and 193 out of 240 in the healthcare sector. These rankings highlight the company’s small-cap profile and the perceived speculative nature of cannabinoid pharmaceutical investments. However, the SPV structure, regulatory alignment, and credible institutional participation offer a fundamentally different risk-return profile compared to early-stage cannabis firms reliant on retail capital or regional dispensary plays.

ThirdGate Capital’s entry into the structure may serve as a validator for future capital flows, particularly from family offices and specialist funds looking for rare disease or neurodevelopmental exposure. Institutional investors have traditionally avoided cannabinoid therapeutics due to regulatory ambiguity and lack of robust trial data. Zelira’s model, backed by formal IND filings and governance discipline, could begin to shift that narrative.

Key takeaways on what this development means for Zelira Therapeutics, its investors, and the cannabinoid biotech sector

• Zelira Therapeutics Limited secured US$33 million in SPV funding from ThirdGate Capital at a post-money valuation of nearly US$66 million for HOPE 1.

• The SPV structure ring-fences HOPE 1’s regulatory and trial pathway while allowing Zelira to retain 39.7% equity through IP contribution and real-world data.

• The investment validates HOPE 1’s FDA 505(b)(2) strategy and potential Orphan Drug Designation, targeting PMS with autism spectrum disorder.

• Zelira will initiate Phase 1 trials and seek IND clearance in early 2026, with iNGENū CRO managing all clinical execution.

• Equity incentives for management are performance-tied to FDA milestones and time-based vesting, aligning upside to execution.

• The SPV model offers a strategic template for biotech firms seeking non-dilutive funding to scale rare disease and cannabinoid therapies.

• Market reaction was sharply positive, with shares rising over 129% in a single session, though Zelira’s long-term valuation uplift depends on clinical progress.

• The move positions Zelira as a structurally innovative player in the cannabinoid and autism-focused biotech segment.